



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Salvatore Silvio Piano**

Organisation/Company: University of Padova

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
08/2020-08/2020	Mallinckrodt Pharmaceuticals	Discussion about the clinical development information (efficacy and safety) of CONFIRM study data and feedback on hepatorenal syndrome type 1 (HRS-1) diagnosis, management experience from European physicians. CONFIRM study investigated the use of terlipressin in the management of Hepatorenal Syndrome type 1 Mallinckrodt is developing terlipressin for the treatment of hepatorenal syndrome type 1 in U.S.A.	
06/2022-(current)	Mallinckrodt Pharmaceuticals	The objectives of the advisory board will be to identify the most common challenges faced by healthcare providers when managing hepatorenal syndrome (HRS) patients, along with gaining insight from European advisors on the optimal approaches for HRS diagnosis, treatment, and volume management Mallinckrodt is developing terlipressin for the treatment of hepatorenal syndrome type 1 in U.S.A.	

Classified as public by the European Medicines Agency

2

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
05/2020-(current)	Grifols SA	Albumin	Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

Period	Products	Therapeutic Indication	Involvement in the repurposing
01/2017-(current)	Simvastatin and Rifaximin	Decompensated cirrhosis	Involvement in the repurposing of a medicinal product where my organisation is collaborating with the champion of the repurposing

2.10 Any other interests or facts

- Involvement in the ANSWER trial (long-term albumin administration in decompensated cirrhosis) sponsored by the Italian Drug Agency (AIFA)
- Involvement as investigator in an investigator-initiated trial comparing terlipressin as continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome
- Involvement as investigator in an investigator-initiated trial comparing terlipressin plus albumin versus midodrine, octreotide and albumin in the treatment of hepatorenal syndrome
- Involvement as a Junior PI in an investigator-initiated trial comparing meropenem plus daptomycin versus ceftazidime in the treatment of nosocomial spontaneous bacterial peritonitis
- Participation in the activities of the European Foundation for the study of Chronic Liver Failure (EF-CLIF)

2.11 Committee for Advanced Therapies (CAT) member or alternate

Classified as public by the European Medicines Agency

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	SALVATORE SILVIO PIANO
Date:	2022-06-10

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template